scholarly journals Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70‐year nationwide cohort

2021 ◽  
Author(s):  
Isabel Smidt‐Nielsen ◽  
Mette Bagger ◽  
Steffen Heegaard ◽  
Klaus Kaae Andersen ◽  
Jens Folke Kiilgaard
Keyword(s):  
Uveal Melanoma ◽  
Tumour Size ◽  
Melanoma Incidence

scholarly journals Ischemia Is Related to Tumour Genetics in Uveal Melanoma

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1004 ◽  
Author(s):  
Niels J. Brouwer ◽  
Annemijn P. A. Wierenga ◽  
Gülçin Gezgin ◽  
Marina Marinkovic ◽  
Gregorius P. M. Luyten ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Messenger Rna ◽  
Tumour Size ◽  
Hypoxia Inducible Factor ◽  
The Cancer Genome Atlas ◽  
Basal Diameter ◽  
Von Hippel Lindau ◽  
The Status ◽  
Using Data ◽  
Tumour Genetics

Hypoxia-inducible factor 1-alpha (HIF1a) and its regulator von Hippel–Lindau protein (VHL) play an important role in tumour ischemia. Currently, drugs that target HIF1a are being developed to treat malignancies. Although HIF1a is known to be expressed in uveal melanoma (UM), it is as yet unknown which factors, such as tumour size or genetics, determine its expression. Therefore, we aimed to determine which tumour characteristics relate to HIF1a expression in UM. Data from 64 patients who were enucleated for UM were analysed. Messenger RNA (mRNA) expression was determined with the Illumina HT-12 v4 chip. In 54 cases, the status of chromosomes 3 and 8q, and BRCA1-associated protein 1 (BAP1) protein expression (immunohistochemistry) were determined. Findings were corroborated using data of 80 patients from the Cancer Genome Atlas (TCGA) study. A significantly increased expression of HIF1a, and a decreased expression of VHL were associated with monosomy 3/loss of BAP1 expression. The relationship between BAP1 loss and HIF1a expression was independent of chromosome 3. The largest basal diameter and tumour thickness showed no relationship with HIF1a. HIF1a expression related to an increased presence of infiltrating T cells and macrophages. From this study, we conclude that HIF1a is strongly related to tumour genetics in UM, especially to loss of BAP1 expression, and less to tumour size. Tumour ischemia is furthermore related to the presence of an inflammatory phenotype.

Increased accuracy in MR diagnosis of uveal melanoma by carbohydrate loading

1998 ◽  
Vol 39 (3) ◽  
pp. 239-242
Author(s):  
K.-Å. Thuomas ◽  
P. Naeser ◽  
A. Wrigstad
Keyword(s):  
Uveal Melanoma ◽  
Spindle Cell ◽  
Spin Echo ◽  
Tumour Size ◽  
Relaxation Times ◽  
Fast Spin Echo ◽  
Subtraction Technique ◽  
Mixed Cell ◽  
Carbohydrate Loading ◽  
Fast Spin

Purpose: To evaluate patients with clinically diagnosed uveal melanoma Material and Methods: Forty-eight consecutive patients were examined with spin-echo (SE) and fast spin-echo (FSE) MR sequences that utilized glucosefructose enhancement together with a subtraction technique on a 1.5 T unit Results: Twenty-seven patients were enucleated and the eyes histologically examined for tumours (spindle cell, mixed cell, and epitheloid cell). The remaining patients were referred for other treatment. There were no significant differences in T2 although T2 was longer in the amelanotic lesions. Carbohydrate loading in combination with a subtraction technique gave: an increased signal intensity; a prolongation of T2; and an increased tumour size. The FSE sequences were as good as the SE sequences in the visualization of uveal malignant melanoma Conclusion: MR imaging performed with carbohydrate loading registers metabolic changes induced in the tumour. This gives the method great validity in the diagnosis of uveal melanoma. The method is especially useful in amelanotic tumours that have longer relaxation times than melanotic tumours. The SE technique can be replaced with the FSE technique

Vasocentric fascicular uveal melanoma. Incidence and re-appraisal of the histological features

2007 ◽  
Vol 92 (1) ◽  
pp. 147-149 ◽  
Author(s):  
I Pecorella ◽  
P Grenga ◽  
E M Vingolo ◽  
A Ciardi
Keyword(s):  
Uveal Melanoma ◽  
Histological Features ◽  
Melanoma Incidence

International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification

2004 ◽  
Vol 114 (1) ◽  
pp. 114-123 ◽  
Author(s):  
Andreas Stang ◽  
Donald Maxwell Parkin ◽  
Jaques Ferlay ◽  
Karl-Heinz Jöckel
Keyword(s):  
Uveal Melanoma ◽  
Incidence Trends ◽  
Melanoma Incidence

Uveal melanoma incidence trends in Canada: a national comprehensive population-based study

2019 ◽  
pp. bjophthalmol-2018-312966 ◽  
Author(s):  
Feras M Ghazawi ◽  
Rami Darwich ◽  
Michelle Le ◽  
Elham Rahme ◽  
Andrei Zubarev ◽  
...  
Keyword(s):  
Geographical Distribution ◽  
Uveal Melanoma ◽  
Developed Countries ◽  
Population Based ◽  
National Study ◽  
Steady Increase ◽  
Incidence Trends ◽  
Melanoma Incidence ◽  
Independent Population ◽  
Canadian Provinces

BackgroundIn the developed countries, uveal melanoma is the most common primary intraocular malignancy in adults. Little is known about the epidemiological and geographical distribution of uveal melanoma in Canada.MethodsTo determine the incidence patterns and geographical distribution of uveal melanoma cases in Canada, we conducted the first comprehensive, population-based national study of this malignancy across all Canadian provinces and territories during 1992–2010 years. We examined two independent population-based registries: the Canadian Cancer Registry and Le Registre Québécois du Cancer using corresponding International Classification of Diseases for Oncology-3rd edition codes for all histological subtypes of uveal melanoma.ResultsWe report that 2215 patients were diagnosed with uveal melanoma, of which 52.1% were males. The average -annual incidence rate of uveal melanoma in Canada was 3.75 cases per million individuals per year (95% CI 3.60 to 3.91). Overall, we report a steady increase in uveal melanoma incidence with an annual increase of 0.074 cases per million individuals per year. Significant differences in the incidence rates of uveal melanoma between Canadian provinces and territories were noted, where the highest crude incidence was in British Columbia and Saskatchewan with rates of 6.38 and 5.47 cases per million individuals per year, respectively.ConclusionsThis work, for the first time, defines the disease burden of uveal melanoma in Canada and highlights important longitudinal, geographical and spatial differences in the distribution of uveal melanoma in Canada.

scholarly journals Clinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6241
Author(s):  
Marina Marinkovic ◽  
Lennart J. Pors ◽  
Vincent van den Berg ◽  
Femke P. Peters ◽  
Ann Schalenbourg ◽  
...  
Keyword(s):  
Optic Nerve ◽  
Visual Impairment ◽  
Uveal Melanoma ◽  
Proton Therapy ◽  
Distant Metastasis ◽  
Proportional Hazards ◽  
Tumour Size ◽  
Cox Proportional Hazards ◽  
Tumour Control ◽  
Melanoma Patients

Objective: To assess oncological and ophthalmological outcomes after international referral of uveal melanoma patients for proton therapy. Materials and Methods: This is a retrospective study among Dutch uveal melanoma patients who were treated in Switzerland with 60.0 CGE proton therapy (in 4 fractions) from 1987 to 2019. All patients were ineligible for brachytherapy due to tumour size and/or proximity to the optic nerve. Time-to-event analyses were performed using Kaplan–Meier’s methodology and Cox proportional hazards models. Results: There were 103 patients (104 eyes) with a median largest tumour diameter of 19 mm (range 6–26 mm). Tumours were localised centrally (11%), mid-peripherally (65%) or peripherally (34%). Median follow-up was 7 years. Five-year local control, distant metastasis-free survival and eye preservation rates were 94%, 70% and 81% respectively. At five years, severe, moderate and mild visual impairment was observed in respectively 79%, 4% and 6% of the patients. Larger tumour volumes and more central tumour localisation were associated with severe visual impairment. After correction for these factors, dose to the macula, optic disc and retina, but not optic nerve was significantly associated with severe visual impairment. Conclusion: International referral for proton therapy yielded good tumour control and eye preservation rates, but risk of distant metastasis and severe visual impairment were substantial, possibly due to the selection of advanced tumour stages and/or central localisation. Dose to the macula may be more relevant than dose to the optic nerve for preservation of visual acuity, which is relevant for the treatment planning of proton therapy.

scholarly journals A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes

2019 ◽  
Vol 104 (4) ◽  
pp. 524-528 ◽  
Author(s):  
Elaine Binkley ◽  
Pierre L Triozzi ◽  
Lisa Rybicki ◽  
Susan Achberger ◽  
Wayne Aldrich ◽  
...  
Keyword(s):  
High Risk ◽  
Adjuvant Therapy ◽  
Uveal Melanoma ◽  
Survival Data ◽  
Low Dose ◽  
Tumour Size ◽  
Prospective Trial ◽  
Choroidal Melanoma ◽  
Primary Therapy ◽  
Interferon Alpha 2B

Background/aimsSurvival after diagnosis of metastasis from uveal melanoma is poor. Identifying individuals at high risk for metastasis and developing adjuvant therapy to prevent clinically apparent metastasis could improve survival. We conducted an adjuvant trial of sequential, low-dose dacarbazine (DTIC) and interferon-alpha-2b (IFN-α−2b) in patients with cytogenetic high-risk uveal melanoma.MethodsPatients diagnosed with iris, ciliary body or choroidal melanoma with high-risk tumour cytogenetics (monosomy 3) were offered adjuvant treatment with low-dose DTIC and IFN-α−2b following primary therapy. Eligible but not enrolled patients were observed for comparison. DTIC was administered at 850 mg/m2 intravenously on days 1 and 28. IFN-α−2b was administered at 3 million units three times a week subcutaneously for 24 weeks beginning at week 9. Hepatic imaging was performed prior to adjuvant therapy and then at least every 6 months. Survival data were collected for 5 years after enrolment.Results33 patients (22%) were enrolled (treatment group), 29 (19%) were eligible but did not enrol (observation group) and 88 (59%) were not eligible. The 5-year metastasis-free survival (MFS) was 64%±9% for treated and 33%±10% for observed patients (p=0.05). The 5-year overall survival (OS) rate was 66%±9% for treated and 37%±10% for observed patients (p=0.02).ConclusionsWhen adjusted for differences in age, tumour size and initial treatment, survival between treated and observed patients was no longer significant (p=0.56 MFS and p=0.92 OS). Differences in baseline tumour characteristics between treated and observed patients can influence interpretation of results.Trial registration numberNCT01100528.

Sign in / Sign up

Export Citation Format

Share Document